220 related articles for article (PubMed ID: 9676764)
1. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
3. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
4. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
7. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
10. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
Goh NS; Veeraraghavan S; Desai SR; Cramer D; Hansell DM; Denton CP; Black CM; du Bois RM; Wells AU
Arthritis Rheum; 2007 Jun; 56(6):2005-12. PubMed ID: 17530640
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
[TBL] [Abstract][Full Text] [Related]
15. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis.
Atamas SP; Yurovsky VV; Wise R; Wigley FM; Goter Robinson CJ; Henry P; Alms WJ; White B
Arthritis Rheum; 1999 Jun; 42(6):1168-78. PubMed ID: 10366109
[TBL] [Abstract][Full Text] [Related]
16. Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavage.
Damjanov N; Ostojic P; Kaloudi O; Alari S; Guiducci S; Stanflin N; Nestorovic B; Knezevic J; Camiciottoli G; Porta F; Pistolesi M; Ibba-Manneschi L; Conforti ML; Candelieri A; Matucci Cerinic M
Respiration; 2009; 78(1):56-62. PubMed ID: 18931474
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
18. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
Calguneri M; Apras S; Ozbalkan Z; Ertenli I; Kiraz S; Ozturk MA; Celik I
Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
[TBL] [Abstract][Full Text] [Related]
20. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
